德勤（Deloitte）：2023年中国生命科学与医疗行业投融资与并购市场展望报告（英文版）（68页）.pdf

1、2023 China Life Sciences and Health Care Investment and M&A Market OutlookDecember,2022Preface 11.M&A Market Realities in the Life Sciences and Health Care Industry 31.1 Review of the M&A Market in Chinas Life Sciences and 4 Healthcare Industry(2021 to the first half of 2022)1.2 Analysis of M&A Tran

2、sactions in the Life Sciences and Healthcare 5 Industry by Segment 1.3 Analysis of Cross-Border M&A Transactions in the Life Sciences 8 and Healthcare Industry 1.4 Changes in Licensing Transactions for Life Sciences Products 132.Review of the Primary Market in the Life Sciences and 18 Healthcare Ind

3、ustry 2.1 Review of the Primary Market in Chinas Life Sciences and 19 Healthcare Industry(2021 to the first half of 2022)2.2 Segment analysis 242.3 Analysis of domestic investment and financing transactions 272.4 Technology companies cross-industry investment 292.5 In-depth analysis of inbound and o

4、utbound investment 303.Outlook for the life sciences and healthcare industry in China 373.1 Continuous advances in the development of Healthy China 38 2030 drawing a people-oriented pharmaceutical and medical development blueprint 3.2 Multi-cooperation model unlocked among multinational 42 pharmaceu

5、tical companies according to the Original and Innovative Development Plan 3.3 Preferential policies herald opportunities for TCM industry 43Content3.4 Accelerated localization and introduction of high-end products 44 by overseas medical equipment companies amid the preference for domestic alternativ

6、es 3.5 Rapid growth of demand for consumer medical services 46 following improvement of industry standardization and post-epidemic consumption rebound 4.Conclusion 475.Appendix 50Top 10 investment and financing transactions by value from 512021 to H1 2022 Top 10 M&A transactions by value from 2021 t